Atezolizumab Phase 3 Clinical Trial Information (IMmotion151)
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
This clinical trial compares the combination of Atezolizumab + Bevacizumab (Avastin) therapy against Sunitinib monotherapy in patients with inoperable metastatic renal cell carcinoma (RCC).
Atezolizumab is an anti-PD-L1 antibody that works by inhibiting the PD-L1 protein, thereby reactivating T-cells to attack cancer cells.
Trial Overview
- Period: August 2015 – October 2019
- Locations: Taiwan, USA, Thailand, Japan, and other regions.
- Target Enrollment: 550 patients
Eligibility Criteria
Inclusion Criteria:
- Age 18 or older.
- Inoperable, locally advanced, or metastatic renal cell carcinoma.
- No prior systemic chemotherapy for metastatic disease.
- Karnofsky Performance Status (PS) of 70% or higher.
Exclusion Criteria:
- Metastasis to the central nervous system (CNS).
- Uncontrolled pleural effusion, ascites, hypercalcemia, or pericardial effusion.
- Other conditions as specified in the full protocol.
For more detailed information, please refer to the clinical trial registry: ClinicalTrials.jp - IMmotion151
#RenalCellCarcinoma #ClinicalTrial #Atezolizumab #Avastin #CancerTreatment
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4